In the News

395 News Items found
A researcher working in an MSK lab
New MSK research investigates whether introducing new mutations could make immunotherapy more effective against some cancers; shows that people in their 90s who underwent lung cancer surgery had positive outcomes; shares lessons on the responsible governance of artificial intelligence in oncology; studies AI-assisted biomarker assessment in lung cancer; and demonstrates a cancer-trained large language model has strong predictive value.
Fiona and Stanley Druckenmiller
Meet Fiona and Stanley Druckenmiller, whose latest venture supports promising new avenues of research for experts at Memorial Sloan Kettering Cancer Center.
An immunofluorescence image of an aged mouse liver
Top Cancer Research Advances at MSK in 2024
MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.
MSK President Craig Thompson
In a first-of-its-kind collaboration, MSK has joined forces with the Chinese Thoracic Oncology Group in an effort to establish a program of clinical trials that are open to patients from both the United States and China.
Charles Rudin with lab member
During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).
MSK's Justin Jee, MD, PhD, and Ed Reznik, PhD, are seen smiling.
Learn about research at MSK that finds obesity can influence driver mutations that produce specific subtypes of cancers, including lung and endometrial cancers.
Microscope image showing lung metastasis
MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
Dr. Piro Lito
In the Lab
MSK investigators report exciting results for a new molecule that can block 16 different mutated forms of the KRAS protein. In the lab, the compound was effective against many cancer cell lines and in mouse models of lung cancer and colorectal cancer.
Dr. Karuna Ganesh and Elizabeth Benitez in the lab.
Metastasis is responsible for about 9 of every 10 cancer deaths, and it remains one of the most daunting and least understood aspects of the disease. Researchers across MSK are approaching a wide variety of metastatic cancer types from many directions.
MSK medical oncologist Michael Morris
Learn about MSK's specialty in treating neuroendocrine cancers.